The basic helix-loop-helix (bHLH) transcription factor, neuronal differentiation 1 (NEUROD1) (also known as BETA2) is involved in the development of neural elements and endocrine pancreas. Less than 10 reports of adult-onset non-insulin-dependent diabetes mellitus (NIDDM) due to heterozygous NEUROD1 mutations and 2 cases with permanent neonatal diabetes mellitus (PNDM) and neurological abnormalities due to homozygous NEUROD1 mutations have been published. A 13 year-old female was referred to endocrine department due to hyperglycemia. She was on insulin therapy following a diagnosis of neonatal diabetes mellitus (NDM) at the age of 9-weeks but missed regular follow-up. Parents are second cousin. There was a significant family history of adult onset NIDDM including patient's father. Auxological measurements were within normal ranges. On laboratory examination blood glucose was 33.2 mmol/L with undetectable c-peptide and glycosylated hemoglobin level of 8.9% (73.8 mmol/mol). She had developed difficulty in walking at the age of 4 years which had worsened over time. On further evaluation, a diagnosis of visual impairment, mental retardation, ataxic gait, retinitis pigmentosa and sensory-neural deafness were considered. Cranial magnetic resonance imaging revealed cerebellar hypoplasia. Molecular genetic analysis using targeted next generation sequencing detected a novel homozygous missense mutation, p.Ile150Asn(c.449T>A), in NEU-ROD1. Both parents and 2 unaffected siblings were heterozygous for the mutation. We report the third case of PNDM with neurological abnormalities caused by homozygous NEUROD1 mutation, the first caused by a missense mutation. Heterozygous carriers of the p.Ile150Asn mutation were either unaffected or diagnosed with diabetes in adulthood. It is currently unclear whether the NEUROD1 heterozygous mutation has contributed to diabetes development in these individuals.
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Heterozygous loss-of-function mutations in NEUROD1 have been reported as a very rare cause of maturity-onset diabetes of the young (MODY) and are associated with increased risk of adult onset diabetes. [6] [7] [8] [9] [10] [11] [12] [13] Homozygous mutations in the NEUROD1 gene are extremely rare with only 2 cases of PNDM and associated neurological abnormalities due to homozygous frameshift mutations reported. 14 Here, we report a novel homozygous missense NEUROD1 mutation in a female patient with PNDM and neurological abnormalities.
The mutation was heterozygous in the unaffected mother and 2 siblings and the father who was diagnosed with non-insulin-dependent diabetes mellitus (NIDDM).
| METHODS

| Genetics testing
The genetic analysis was performed at the Molecular Genetics Labo- The bioinformatics tools SIFT, PolyPhen-2 and Align GVGD were accessed through the ALAMUT software (Interactive Biosoftware, Rouen, France) to predict the effect of the novel variant on the NEU-ROD1 protein.
| CASE REPORTS
A 13.4-year-old female was referred to our endocrine department due to hyperglycemia. She was on insulin therapy following a diagnosis of NDM since postnatal 9 weeks (reportedly), but missed her regular follow-up visits. She was born after 40 weeks uneventful gestation to second cousin parents via vaginal delivery. Birth weight was 2500 g. There was a family history of adult-onset NIDDM in 3 consecutive generations including her father ( Figure 1 ). All family members developed NIDDM in their 50s ( Figure 1 and Table 1 ). The family history was otherwise unremarkable. The proband developed Abdominal ultrasonography showed a pancreas with normal size and parenchymal echotexture. Genetics and Genomics (ACMGS) guidelines. 16 Both parents and 2 unaffected siblings were heterozygous for the mutation (Table 1 , Figure 1 ). Samples from the other members with non-insulindependent diabetes were not available for testing.
| Mutation analysis results
| DISCUSSION
We here present a case with PNDM and neurological abnormalities including developmental delay, cerebellar hypoplasia, visual impairment, and sensory-neural deafness due to a novel homozygous missense NEUROD1 mutation. To the best of our knowledge this is the first case of syndromic neonatal diabetes caused by a homozygous missense NEUROD1 mutation (the 2 previously reported cases had frameshift mutations). Only one of the heterozygous carriers in the families has diabetes (the patient's father who was diagnosed with non-insulin-dependent diabetes at 52 years of age, whilst the others are unaffected. Our report confirms the role of the NEUROD1 gene in the development of the pancreas and nervous system in human.
NEUROD1 is a tissue-specific bHLH transcription factor that plays a fundamental role in the development, differentiation, and maintenance of neural elements and endocrine pancreas. Table 2 ). The 2 previously reported cases were homozygous for frameshift mutations (c.364dupG and c.427_428del) which are likely to result in the translation of a truncated NEUROD1 protein lacking the transactivation domain which has been shown to be important for interaction of NEUROD1 with its main coactivator, p300.
14,24
Proteins lacking the transactivation domain are likely to have no biological activity, as shown for a previously reported frameshift mutation (c.616dupC, p.His206Profs*38) identified in a patient with MODY. 6, 14 In our patient, we identified a novel missense mutation (c.449T>A; p.Ile150Asn) in exon 2 of NEUROD1 which causes an amino acid change (Ile to Asn) in the highly conserved DNA-binding domain of the NEUROD1 protein (Figure 4 ). Current evidence suggests that this mutation is likely to be pathogenic. Our patient, similar to the 2 previously reported cases, had neonatal diabetes with normal pancreas size on scanning and normal pancreatic exocrine function.
Low birthweight for gestational age was reported in all 3 cases and suggests severe intrauterine insulin deficiency. These findings confirm that NEUROD1 plays a key role in pancreatic development at the stage of the islet cell differentiation rather than during the first phase of pancreatic development. Consistently, Neurod1 deficient mice develop severe diabetic ketoacidosis and die shortly after birth. 25 Histological investigation of the pancreas in these animals showed impaired islet development with reduced endocrine (particularly beta) cells. 25 Extra-pancreatic clinical features including neurodevelopmental delay, visual impairment due to retinal pigmentary epithelial atrophy, severe sensory-neural deafness, and cerebellar hypoplasia were consistent with the 2 previously reported cases and with the findings in Neurod1 deficient mice (Table 2) . 14, [19] [20] [21] 25 These findings confirm the critical role of NEUROD1 in development and maintenance of neural elements. Indeed, in the first report, Neurod1 deficient mice showed all of the above features, but did not show any structural or histological abnormality in the brain. 25 However, in Neurod1 deficient mice which were rescued either by expressing a transgene encoding the mouse Neurod1 gene under the insulin promoter or by crossing the null mutation into a different genetic background to reduce the severity of the diabetes, the rescued Neurod1 deficient mice showed a neurological phenotype similar to the human condition consisting of impaired balance, ataxic gait, circling, and swaying head movement as a result of impaired cerebellar development. 14, [19] [20] [21] Moreover, rescued Neurod1 deficient mice had hearing loss and visual impairment suggesting severe sensory neuronal defects in the inner ear and neural retina. 19, 26, 27 The main clinical feature differing between mice and humans was epilepsy, which was not detected in humans (although one of the previously reported cases developed 2 hypoglycaemic seizures) but is seen in mice. 14, 20 Our patient also suffered from seizures and was on antiepileptic therapy at admission. However, laboratory inves- Recently, a NEUROD1 homozygous missense mutation, p.
Val242Ile, has been identified in a consanguineous family with autosomal recessive non-syndromic retinitis pigmentosa. 28 This variant was identified by whole-exome sequencing and was predicted to affect a highly conserved amino acid. Different in silico analysis algorithms yielded prediction scores ranging from "damaging" to "benign." 28 Segregation analysis was consistent with the variant being causative, supporting the essential role of NEUROD1 in maintaining adult photoreceptors in humans. 26, 28 It is interesting that these cases had isolated retinitis pigmentosa with no neurological features or disorders in glucose metabolism. It is possible that there is a specific phenotype-genotype relationship resulting in specific NEUROD1
mutations causing different phenotypes. Functional studies would be needed in order to elucidate the impact of different missense mutations on the NEUROD1 protein.
Heterozygous carriers of NEUROD1 mutations have been reported with a MODY phenotype or adult onset NIDDM. [6] [7] [8] [9] [10] [11] [12] [13] Although the clinical phenotype can be similar to MODY in terms of early onset, autoantibody negative, non-obese individuals, a remarkable incomplete penetrance has been shown among family members carrying an identical heterozygous NEUROD1 mutation. [6] [7] [8] [9] [10] [11] [12] [13] Consistently with this, in the family we are reporting, although there was a family history of NIDDM in 3 consecutive generations which is usually considered typical for MODY, only the patient's father was heterozygous for the NEUROD1 mutation and affected with diabetes, whilst the 44-year-old mother and 2 siblings who were also heterozygous for the mutation were found to have normal glucose metabolism. Regarding the other family members affected with diabetes, except for the paternal aunt and uncle who are obese, the other family members were reported as either overweight or not obese. All of them were on oral antidiabetic (OAD) therapy with requirement of insulin and OAD combination in 2 obese subjects. Furthermore, all had developed diabetes after the age of 50 years which is not consistent with a diagnosis of MODY. Finally, and most strikingly, all the individuals with diabetes were on the paternal side of the family, if heterozygosity for the NEUROD1 mutation is sufficient to cause diabetes you would expect there to be a similar number of individuals with diabetes on the maternal side of the family. Taking all of these findings into consideration, it is currently unclear whether the NEU-ROD1 heterozygous mutation contributes to diabetes development in these individuals especially in the absence of co-segregation studies.
Follow up of the heterozygous family members and/or molecular genetics analysis of other diabetic and non-diabetic members will be informative for the potential role of the heterozygous p.Ile150Asn mutation in the development of adult onset diabetes.
In conclusion, we present a case of PNDM with neurological abnormalities due to a novel homozygous missense NEUROD1 muta- 
